Overview

Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL (PCR)

Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety of Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in the Treatment of Relapsed or Refractory DLBCL
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-sen University
Collaborator:
Chipscreen Biosciences, Ltd.
Treatments:
Antibodies
Rituximab